Hutchison China MediTech (HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumours (NET). The data support a China NDA submission (imminent), with surufatinib likely to be the first of HCM’s non-partnered assets to reach the market (late 2020). NET tumours are highly prevalent, fragmented in primary origin and are an unmet medical need. Surufatinib could be the first universal drug to treat NET in all patients regardless of
09 Oct 2019
Hutchison China MediTech - Surufatinib NETs solid data at ESMO
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hutchison China MediTech - Surufatinib NETs solid data at ESMO
HUTCHMED (China) Limited (HCM:LON) | 267 -2.7 (-0.4%) | Mkt Cap: 2,326m
- Published:
09 Oct 2019 -
Author:
Dr Susie Jana -
Pages:
8
Hutchison China MediTech (HCM) presented robust SANET-ep Phase III China data at ESMO 2019 on surufatinib in non-pancreatic neuroendocrine tumours (NET). The data support a China NDA submission (imminent), with surufatinib likely to be the first of HCM’s non-partnered assets to reach the market (late 2020). NET tumours are highly prevalent, fragmented in primary origin and are an unmet medical need. Surufatinib could be the first universal drug to treat NET in all patients regardless of